The Journal of Practical Medicine >
Impact of ultrasound guided interscalene versus axillary brachial plexus block on patency rate of arteriovenous fistula
Received date: 2025-03-06
Online published: 2025-05-20
Objective To compare the safety and efficacy of various brachial plexus block techniques using local anesthesia (LA) in patients undergoing their first radiocephalic arteriovenous fistula (RCAVF) surgery. Methods Patients were randomly allocated into three groups: LA, interscalene brachial plexus block (ISBPB), and axillary brachial plexus block (ABPB). Ultrasound was utilized to evaluate the pre- and post-anesthesia changes in vessel diameter and blood flow. Postoperative follow-up assessments were performed at three days and three months to determine fistula patency. Results Immediate patency rates were 92.52% (LA), 96.26% (ISBPB), and 95.33% (ABPB), with no statistically significant differences among the groups (χ2 = 1.615, P = 0.446). However, at three months, primary patency rates differed significantly among the groups (χ2 = 22.691, P < 0.001). Specifically, the ISBPB group (83.18%) exhibited significantly higher patency compared to the LA group (57.01%) (χ2 = 17.477, P < 0.001). Similarly, the ABPB group (80.37%) demonstrated better patency than the LA group (χ2 = 13.580, P < 0.001). Regarding respiratory complications, they were more prevalent in the ISBPB group (15.89%) compared to the LA group (2.80%) (χ2 = 9.761, P = 0.002) and the ABPB group (0.93%) (χ2 = 14.377, P < 0.001). No significant difference was observed between the LA and ABPB groups in terms of respiratory complications (χ2 = 1.019, P = 0.313). Conclusions Both ISBPB and ABPB demonstrated superior primary patency compared to LA. Nevertheless, ABPB exerted a lesser impact on respiratory function and provided a more comfortable surgical experience for ESRD patients.
Chi ZHANG , Xiao LI , Xiang WEI , Gangyi CHEN , Hongmei LI , Kejia WANG , Junyi ZHENG . Impact of ultrasound guided interscalene versus axillary brachial plexus block on patency rate of arteriovenous fistula[J]. The Journal of Practical Medicine, 2025 , 41(9) : 1293 -1298 . DOI: 10.3969/j.issn.1006-5725.2025.09.004
| 1 | Diseases Kidney : Improving Global Outcomes(KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease [J]. Kidney Int, 2024,105(4S):S117-S314. |
| 2 | GIST K M, FUHRMAN D Y, DEEP A, et al. Continuous Renal Replacement Therapy: Current State and Future Directions for Worldwide Practice [J]. Pediatr Crit Care Med, 2024, 25(6): 554-560. doi:10.1097/pcc.0000000000003477 |
| 3 | 武丹,陈波,陈静,等. 基于2种模型的终末期肾脏病直接经济负担预测分析[J]. 现代医药卫生,2024,40(17):3045-3048. |
| 4 | 张凤,蒋红樱. 自体动静脉内瘘功能障碍的防治进展[J]. 实用医学杂志,2024,40(13): 1767-1770. |
| 5 | 杨昆鑫,陆迪涵,刘艺,等. 臂丛神经阻滞对动静脉造瘘术后血管通畅率的影响[J]. 临床外科杂志,2024,32(6):593-598. |
| 6 | AITKEN E, JACKSON A, KEARNS R, et al. Effect of regional versus local anaesthesia on outcome after arteriovenous fistula creation: a randomised controlled trial [J]. Lancet, 2016, 388(10049):1067-1074. doi:10.1016/s0140-6736(16)30948-5 |
| 7 | AITKEN E, KEARNS R, GAIANU L, et al. Long-Term Functional Patency and Cost-Effectiveness of Arteriovenous Fistula Creation under Regional Anesthesia: a Randomized Controlled Trial [J]. J Am Soc Nephrol, 2020, 31(8): 1871-1882. doi:10.1681/asn.2019111209 |
| 8 | HUI M, MA J, YANG H, et al. ESKD Risk Prediction Model in a Multicenter Chronic Kidney Disease Cohort in China: A Derivation, Validation, and Comparison Study [J]. J Clin Med, 2023, 12(4):1504. doi:10.3390/jcm12041504 |
| 9 | TROUPES C, PNG C Y M, BHATTARAI P, et al. Small Caliber Distal Cephalic Veins Undergo Significant Dilation under Anesthesia and Can Successfully Be Used for Arteriovenous Fistula Creation [J]. Ann Vasc Surg, 2023, 96: 316-321. doi:10.1016/j.avsg.2023.03.027 |
| 10 | 王群, 梁黎明, 孔祥雷. 交感神经激活在自体动静脉内瘘新生内膜增生中的作用 [J]. 中国血液净化, 2023, 22(6): 442-445. |
| 11 | ROBBIN M L, GREENE T, CHEUNG A K, et al. Arteriovenous Fistula Development in the First 6 Weeks after Creation [J]. Radiology, 2016, 279(2): 620-629. doi:10.1148/radiol.2015150385 |
| 12 | MOYA-RODRíGUEZ A, XIE B, COOK D, et al. Creating patient-specific vein models to characterize wall shear stress in hemodialysis population [J]. Comput Struct Biotechnol J, 2022, 20: 5729-5739. doi:10.1016/j.csbj.2022.10.010 |
| 13 | KNAPP M, TU X, WU R. Vascular endothelial dysfunction, a major mediator in diabetic cardiomyopathy [J]. Acta Pharmacol Sin, 2019, 40(1): 1-8. doi:10.1038/s41401-018-0042-6 |
| 14 | KIM R. Effects of surgery and anesthetic choice on immunosuppression and cancer recurrence [J]. J Transl Med, 2018, 16(1): 8. doi:10.1186/s12967-018-1389-7 |
| 15 | HOSTALRICH A, BOISROUX T, SEGAL J, et al. Assessment of Duplex Ultrasound Carried Out by the Vascular Surgeon After Locoregional Anesthesia for Preferred Arteriovenous Fistula Access [J]. Ann Vasc Surg, 2022, 83: 117-123. doi:10.1016/j.avsg.2021.11.014 |
| 16 | 韦文君,林奕梅.单次正中神经及桡神经阻滞与臂丛神经阻滞在上肢动静脉造瘘手术中的应用对比[J].中国科技期刊数据库医药,2024(5):0136-0139. |
| 17 | PANDE A, SEN I M, GUPTA A, et al. Perineural low dexamethasone dose as adjuvant in supraclavicular brachial plexus block for arteriovenous fistula creation in end stage renal disease: A randomized controlled trial [J]. Braz J Anesthesiol, 2023, 73(6): 744-750. doi:10.1016/j.bjane.2021.10.012 |
| 18 | WAHAL C, GRANT S A, GADSDEN J, et al. Femoral artery block (FAB) attenuates thigh tourniquet-induced hypertension: a prospective randomized, double-blind, placebo-controlled trial [J]. Reg Anesth Pain Med, 2021, 46(3): 228-232. doi:10.1136/rapm-2020-102113 |
| 19 | LI X T, TIAN T, XUE F S. Hemidiaphragmatic paresis associated with interscalene nerve block [J]. Can J Anaesth, 2022, 69(10): 1311-1312. doi:10.1007/s12630-022-02289-y |
| 20 | XU L, GESSNER D, KOU A, et al. Rate of occurrence of respiratory complications in patients who undergo shoulder arthroplasty with a continuous interscalene brachial plexus block and associated risk factors: an infographic [J]. Reg Anesth Pain Med, 2023, 48(11): 547-548. doi:10.1136/rapm-2023-104578 |
| 21 | DEO R, DUBIN R F, REN Y, et al. Proteomic cardiovascular risk assessment in chronic kidney disease [J]. Eur Heart J, 2023, 44(23): 2095-2110. doi:10.1093/eurheartj/ehad115 |
| 22 | CHAO C T, LIN S H. Uremic Toxins and Frailty in Patients with Chronic Kidney Disease: A Molecular Insight [J]. Int J Mol Sci, 2021, 22(12):6270. doi:10.3390/ijms22126270 |
/
| 〈 |
|
〉 |